Podcast Notes Key Takeaways

• Many more people have PTSD from non-military causes than military causes
• Suicide attempts are carried out by 28% of PTSD sufferers
• Roughly $20 billion per yer is paid out in disability payments to PTSD sufferers in the U.S.
• Results of a recent Phase II clinical trial examining the effectiveness of using MDMA in conjunction with talk therapy to treat PTSD:
  • Of the people who had therapy + no MDMA, 23% no longer had PTSD at the 2-month follow up
  • Of the people who had therapy + MDMA, 56% no longer had PTSD at the 2 month follow up
    • At the 1-year follow up, this number jumped to 68%
  • The treatment worked regardless of the cause of the PTSD (even complex PTSD caused by things like childhood sexual abuse)
• Phase III clinical trials examining MDMA’s effectiveness at treating PTSD are currently underway
• It is estimated that by the end of 2021, MDMA will be approved for the treatment of PTSD
  • It’s estimated that the treatment will cost between $10-15k
• MAPS is planning some studies with MDMA for eating disorder patients (because of its ability to facilitate self-acceptance)

Read the full notes @ podcastnotes.org



Subscribe to the After On Podcast Podcast

The drug known as Molly, Ecstasy and MDMA may soon get regulatory approved for therapeutic use, thanks to a 34-year campaign waged by Rick Doblin. Rick and I discuss all of this, plus his own unique story.